How to use the speech recognition tool?
A Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt’s Macular Degeneration.
Status of the trial: Active, Not recruiting
Orphan Drug Recognition: NA
Inclusion: Patient must have received a subretinal injection of SAR422459. Patient must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit.
Exclusion: Patient did not receive SAR422459 as part of the TDU13583 protocol
Funder Type: industry
Principal location of the trial
HCP: Principal investigators
HCP: Other investigators